Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity ...

ARK Innovation ETF's 12.5% annual total return since inception only slightly lags the S&P 500, but with its high volatility, ARKK's Sharpe Ratio is significantly worse. The ETF's top 10 holdings ...

Journal policy recused the author from having any role in the peer review of this manuscript. Stock and Other Ownership Interests: Scorpion Therapeutics, Vividion Therapeutics, Fore Biotherapeutics, ...